Home › NDC Lookup › Ingredients › Methocarbamol › 69584-0611-10
Methocarbamol 500 mg Tablet, 100-count — NDC 69584-0611-10 package photo

Methocarbamol 500 mg Tablet, 100-count

by Oxford Pharmaceuticals, LLC · 100 TABLET in 1 BOTTLE (69584-611-10)
NDC 69584-0611-10
🏷️ FDA NDC (as labeled) 69584-611-10 billing pads the product segment with a zero
This package
Contains100-count Cost per ea$0.0397 NADAC Per package$3.97 / 100 tablets Pack sizes4 compare ↓
Also priced by: Medicaid pays $0.1358/unit — full pricing hub ↓
Also comes in: 90 tablets 69584-0611-09 500 tablets 69584-0611-50 1000 tablets 69584-0611-90
Rx only Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Methocarbamol (different manufacturers) — 2 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Mar 21, 2025 — Lack of Assurance of Sterility: Media fill with bacterial contamination (Somerset Therapeutics Private Limited) · FDA recall D-0354-2025
Class I · Feb 15, 2024 — Presence of Particulate Matter (Eugia US LLC) · FDA recall D-0440-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

🆔 Identity & classification

FDA NDC (as labeled) 69584-611-10
Product NDC 69584-611
11-digit billing NDC 69584061110
NCPDP billing unit EA — each (per item)
RxCUI 197943, 197944
UNII 125OD7737X
Application # ANDA040489
SPL Set ID 06dc72a6-ef3a-425a-9194-a9d228093cc4
Established class (EPC) Muscle Relaxant
Physiologic effect Centrally-mediated Muscle Relaxation
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2019-08-15
Route ORAL
Dosage form TABLET
Substance METHOCARBAMOL
GPI-14 75100070000305
GPI class Methocarbamol
GCN Seq No 004654
GCN 17892
HICL code 001938
Ingredient (HICL) Methocarbamol
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H6
Therapeutic class — intermediate (HIC2) Drugs Acting Principally On The Midbrain
HIC3 code H6H
Therapeutic class — specific (HIC3) Skeletal Muscle Relaxants
AHFS code 12:20.04.00
AHFS class Centrally Acting Skeletal Muscle Relaxnt
FDB label name METHOCARBAMOL 500 MG TABLET
FDB brand name Methocarbamol
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AA · RLD · RS
Why two NDCs? The FDA registers this code as 69584-611-10 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 69584-0611-10. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Muscle Relaxant class.

Pharmacologic class Muscle Relaxant
Drug family (ATC) Carbamic acid esters
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerOxford Pharmaceuticals, LLC
Application holderOXFORD PHARMACEUTICALS LLC
FDA applicationANDA040489 (ANDA)
Labeler code69584
First marketedAug 2019
Product typeHuman Prescription Drug
Portfolio35 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name METHOCARBAMOL 500 MG TABLET Ingredient Methocarbamol
📖 What it is MedlinePlus · NLM

Methocarbamol is used with rest, physical therapy, and other measures to relax muscles and relieve pain and discomfort caused by strains, sprains, and other muscle injuries. Methocarbamol is in a class of medications called muscle relaxants. It works by slowing activity in the nervous system to allow the body to relax

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Methocarbamol is a muscle relaxant that works through your central nervous system — your brain and spinal cord — rather than directly on the muscles themselves. It's thought to red...
  • What exactly does methocarbamol do? Will it make my muscles stop hurting?
  • You really should not. Methocarbamol already causes drowsiness and slows your central nervous system down. Adding alcohol on top of that significantly increases those effects — we'...
  • Be careful, especially when you first start taking it. Methocarbamol can impair your alertness, coordination, and reaction time. Don't drive or operate heavy machinery until you kn...
📖 Read our full Methocarbamol guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

💊 What it looks like

Color White
ShapeCapsule
Imprint612;O
Size19 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII RDH86HJV5Z
    Povidone K90 is a synthetic polymer made from a chemical called vinyl pyrrolidone. It acts as a binder to hold pill ingredients together and as a dispersant to help the medicine break down and dissolve properly in your body.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
  • UNII 5856J3G2A2
    A starch-based powder made from potatoes and processed with sodium. It acts as a disintegrant, helping the tablet or capsule break apart quickly in the stomach so the medicine can be absorbed.
  • UNII O8232NY3SJ
    A plant-based carbohydrate derived from corn kernels. It acts as a filler to add bulk, a binder to hold ingredients together, and a disintegrant to help the tablet break apart in your stomach for absorption.
  • UNII 4ELV7Z65AP
    Stearic acid is a fatty acid derived from plant or animal sources. It acts as a binder and lubricant in tablets and capsules, helping them hold together and flow smoothly during manufacturing.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

7 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.040 $3.97 / 100 tablets
Medicaid paysCMS SDUD · 12 mo $0.1358 $13.58 / 100 tablets
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Dec 2021 Jul 2022 Dec 2025 Aug 2026 $0.071 $0.036
▼ Down 36% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Methocarbamol 500 mg 00904-7057-61 Major 100 tablets $0.040 AA Availability likely —
Methocarbamol 500 mg 31722-0533-01 Camber 1200 tablets $0.040 AA Availability likely —
Methocarbamol 500 mg 43547-0405-10 Solco 100 tablets $0.040 AA Availability likely —
Methocarbamol 500 mg 50268-0520-15 AvPAK 50 tablets $0.040 AA Availability likely —
Methocarbamol 500 mg 59651-0340-01 Aurobindo 100 tablets $0.040 AA Availability likely —
Methocarbamol 500 mg 60687-0559-01 American 100 tablets $0.040 AA Availability likely —
Methocarbamol Tablets, USP, 500 mg 63561-0173-01 Granulation 100 tablets $0.040 AA Availability likely —
Methocarbamol 500 mgthis 69584-0611-10 Oxford 100 tablets $0.040 AA Availability likely —
Methocarbamol 500 mg 70010-0754-01 Granules 100 tablets $0.040 AA Availability likely —
Methocarbamol 500 mg 76385-0123-01 UNICHEM 100 tablets $0.040 AA Availability likely —
Methocarbamol 500 mg 00615-8506-05 NCS 15 tablets — AA FDA listed —
Methocarbamol Tablets, USP, 500 mg 10135-0722-01 Marlex 100 tablets — AA FDA listed —
Methocarbamol 500 mg 15014-0910-10 GENTEX 100 tablets — AA FDA listed —
Methocarbamol 500 mg 35561-0212-12 Bostal 100 tablets — AB FDA listed —
Methocarbamol 500 mg 43063-0903-18 PD-Rx 18 tablets — AA FDA listed —
Methocarbamol 500 mg 45865-0242-30 Medsource 30 tablets — AA FDA listed —
Methocarbamol 500 mg 50090-0182-00 A-S 40 tablets — AA FDA listed —
Methocarbamol 500 mg 50090-0183-00 A-S 10 tablets — AA FDA listed —
Methocarbamol 500 mg 50090-0184-00 A-S 40 tablets — AA FDA listed —
Methocarbamol 500 mg 50090-3557-01 A-S 20 tablets — AA FDA listed —
Methocarbamol 500 mg 50090-3570-00 A-S 10 tablets — AA FDA listed —
Methocarbamol 500 mg 50090-3578-00 A-S 40 tablets — AA Discontinued —
Methocarbamol 500 mg 50090-3756-00 A-S 40 tablets — AA FDA listed —
Methocarbamol 500 mg 50090-4793-00 A-S 40 tablets — AA FDA listed —
Methocarbamol 500 mg 50090-5846-00 A-S 10 tablets — AA FDA listed —
Methocarbamol 500 mg 50090-5847-00 A-S 40 tablets — AA Discontinued —
Methocarbamol 500 mg 50090-5907-00 A-S 40 tablets — AA FDA listed —
Methocarbamol 500 mg 51407-0467-01 Golden 100 tablets — AA FDA listed —
Methocarbamol 500 mg 51655-0195-51 Northwind 40 tablets — AA FDA listed —
Methocarbamol 500 mg 51655-0574-52 Northwind 30 tablets — AA FDA listed —
Methocarbamol 500 mg 55154-2129-00 Cardinal 10 tablets — AA FDA listed —
Methocarbamol 500 mg 55154-2334-00 Cardinal 10 tablets — AA FDA listed —
Methocarbamol 500 mg 55700-0890-60 Quality 60 tablets — AA Discontinued —
Methocarb 500-EZS 59088-0724-00 PureTek 100 tablets — — FDA listed —
Methocarbamol 500 mg 60760-0592-90 St. 90 tablets — AA FDA listed —
Methocarbamol 500 mg 61919-0368-07 DIRECT 7 tablets — AA FDA listed —
Methocarbamol 500 mg 62207-0754-41 Granules 24 tablets — AA FDA listed —
Methocarbamol 500 mg 63187-0087-00 Proficient 100 tablets — AA FDA listed —
Methocarbamol 500 mg 63629-1123-01 Bryant 500 tablets — — FDA listed —
Methocarbamol 500 mg 63629-1622-00 Bryant 15 tablets — AA FDA listed —
Methocarbamol 500 mg 63629-2417-01 Bryant 500 tablets — AA Discontinued —
Methocarbamol 500 mg 63629-2418-01 Bryant 100 tablets — AA FDA listed —
Methocarbamol 500 mg 63629-4882-01 Bryant 60 tablets — AA FDA listed —
Methocarbamol 500 mg 63629-9288-01 Bryant 100 tablets — AA FDA listed —
Methocarbamol 500 mg 67046-0538-03 Coupler 30 tablets — AA FDA listed —
Methocarbamol 500 mg 67296-1435-01 Redpharm 15 tablets — AA FDA listed —
Methocarbamol 500 mg 67296-2193-01 Redpharm 15 tablets — AA FDA listed —
Methocarbamol 500 mg 67296-2197-01 Redpharm 15 tablets — AA FDA listed —
Methocarbamol 500 mg 68071-3636-06 NuCare 6 tablets — AA FDA listed —
Methocarbamol 500 mg 68071-4520-02 NuCare 20 tablets — AA FDA listed —
Methocarbamol 500 mg 68788-7973-03 Preferred 30 tablets — AA FDA listed —
Methocarbamol 500 mg 68788-8213-03 Preferred 30 tablets — AA FDA listed —
Methocarbamol 500 mg 68788-8822-01 Preferred 100 tablets — AA FDA listed —
Methocarbamol 500 mg 68788-8867-03 Preferred 30 tablets — AA FDA listed —
Methocarbamol 500 mg 68788-8880-03 Preferred 30 tablets — AA FDA listed —
Methocarbamol 500 mg 69306-0500-01 Doc 100 tablets — AA FDA listed —
Methocarbamol 500 mg 69306-0510-01 Doc 100 tablets — AA FDA listed —
Methocarbamol 500 mg 70518-1723-03 REMEDYREPACK 30 tablets — AA FDA listed —
Methocarbamol 500 mg 70518-4603-00 REMEDYREPACK 40 tablets — AA FDA listed —
Methocarbamol 500 mg 70868-0910-10 Key 100 tablets — AA FDA listed —
Methocarbamol 500 mg 71205-0103-20 Proficient 20 tablets — AA FDA listed —
Methocarbamol 500 mg 71205-0167-30 Proficient 30 tablets — AA FDA listed —
Methocarbamol 500 mg 71205-0375-20 Proficient 20 tablets — — FDA listed —
Methocarbamol 500 mg 71335-0970-00 Bryant 15 tablets — AA FDA listed —
Methocarbamol 500 mg 71335-1795-00 Bryant 15 tablets — — FDA listed —
Methocarbamol 500 mg 71335-2383-00 Bryant 15 tablets — AA FDA listed —
Methocarbamol 500 mg 71335-2794-00 Bryant 15 tablets — AA FDA listed —
Methocarbamol 500 mg 71335-3105-01 Bryant 60 tablets — AA FDA listed —
Methocarbamol 500 mg 71610-0599-30 Aphena 30 tablets — — FDA listed —
Methocarbamol 500 mg 71610-0832-30 Aphena 30 tablets — AA FDA listed —
Methocarbamol 500 mg 72162-1363-01 Bryant 100 tablets — — FDA listed —
Methocarbamol 500 mg 72162-1929-01 Bryant 100 tablets — AA FDA listed —
Methocarbamol Tablets, USP, 500 mg 72162-2487-01 Bryant 100 tablets — AA FDA listed —
Methocarbamol 500 mg 72189-0284-30 DirectRx 30 tablets — AA FDA listed —
Methocarbamol 500 mg 72189-0665-30 Direct_rx 30 tablets — AA FDA listed —
Methocarbamol 500 mg 72789-0012-18 PD-Rx 18 tablets — AA FDA listed —
Methocarbamol 500 mg 72789-0021-01 PD-Rx 100 tablets — AA FDA listed —
Methocarbamol 500 mg 72789-0110-40 PD-Rx 40 tablets — AA FDA listed —
Methocarbamol 500 mg 72789-0397-01 PD-Rx 100 tablets — AA FDA listed —
Methocarbamol 500 mg 72789-0428-18 PD-Rx 18 tablets — AA FDA listed —
Methocarbamol Tablets, USP, 500 mg 72789-0481-01 PD-Rx 100 tablets — AA FDA listed —
Methocarbamol Tablets, USP, 500 mg 72789-0499-18 PD-Rx 18 tablets — AA FDA listed —
Methocarbamol 500 mg 72865-0233-01 XLCare 100 tablets — AA FDA listed —
Methocarbamol 500 mg 76420-0626-01 Asclemed 100 tablets — AA FDA listed —
Methocarbamol 500 mg 76420-0667-01 Asclemed 100 tablets — AA FDA listed —
Methocarbamol 500 mg 76420-0893-01 Asclemed 100 tablets — AA FDA listed —
Methocarbamol 500 mg 80425-0138-01 Advanced 60 tablets — AA FDA listed —
Methocarbamol 500 mg 80425-0275-01 Advanced 30 tablets — AA FDA listed —
Methocarbamol 500 mg 80425-0283-01 Advanced 30 tablets — AA FDA listed —
Methocarbamol 500 mg 80425-0577-01 Advanced 30 tablets — AA FDA listed —
Methocarbamol 500 mg 80425-0578-01 Advanced 30 tablets — AA FDA listed —
Methocarbamol 500 mg 80425-0579-01 Advanced 30 tablets — AA FDA listed —
Methocarbamol 500 mg 82804-0121-30 Proficient 30 tablets — AA FDA listed —
Methocarbamol 500 mg 82804-0273-30 Proficient 30 tablets — AA FDA listed —
Methocarbamol 500 mg 82804-0954-00 Proficient 100 tablets — AA FDA listed —
Methocarbamol 500 mg 85509-1910-01 PHOENIX 100 tablets — AA FDA listed —
Methocarbamol 500 mg 85509-2910-01 PHOENIX 100 tablets — AA FDA listed —
Methocarbamol 500 mg 87063-0040-01 Asclemed 100 tablets — AA FDA listed —
Methocarbamol 500 mg 87063-0135-01 ASCLEMED 100 tablets — AA FDA listed —
Methocarbamol 500 mg 85534-0021-00 HAWAII 30 tablets — AA FDA listed —
Methocarbamol 500 mg 87441-0057-01 Unit 30 tablets — AA FDA listed —
Methocarbamol 500 mg 85534-0057-00 HAWAII 30 tablets — AA FDA listed —
Methocarbamol Tablets, USP, 500 mg 72789-0581-40 PD-Rx 40 tablets — AA FDA listed —
Methocarbamol 500 mg 82461-0722-90 Medcore 90 tablets — AA FDA listed —
Methocarbamol 500 mg 67046-1177-03 Coupler 30 tablets — AA FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2019
On the market since
Aug 2019
📍
2026
Currently FDA-listed
7 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 69584-0611-10, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
35.4K
Units reimbursed last 4 qtrs
2.1M
Gross reimbursed last 4 qtrs
$279.3K
Avg / prescription
$7.90
Avg / unit
$0.1358
Latest quarter Q4 2025
11.4KRx
Medicaid pays / ea
$0.1358
gross reimbursed
vs
NADAC / ea
$0.0397
acquisition cost
=
Spread
+$0.0961
+242% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
32% FFS 68% MCO
Fee-for-service · 11,209 Rx Managed care · 24,153 Rx
State Medicaid map
Alaska: 19,279 units · 2,630 per 100k residents AK Maine: 9,318 units · 668 per 100k residents ME Washington: 332,936 units · 4,262 per 100k residents WA Idaho: 43,821 units · 2,231 per 100k residents ID Montana: 37,237 units · 3,289 per 100k residents MT North Dakota: 6,603 units · 843 per 100k residents ND Minnesota: 27,202 units · 474 per 100k residents MN Wisconsin: 9,903 units · 168 per 100k residents WI Michigan: 35,944 units · 358 per 100k residents MI New York: 60,139 units · 307 per 100k residents NY Vermont: 3,336 units · 516 per 100k residents VT New Hampshire: 2,736 units · 195 per 100k residents NH Oregon: 208,695 units · 4,930 per 100k residents OR Nevada: 26,304 units · 824 per 100k residents NV Wyoming: no data reported WY South Dakota: 3,506 units · 382 per 100k residents SD Iowa: 4,659 units · 145 per 100k residents IA Illinois: 26,699 units · 213 per 100k residents IL Indiana: 29,355 units · 428 per 100k residents IN Ohio: 67,422 units · 572 per 100k residents OH Pennsylvania: 57,210 units · 441 per 100k residents PA New Jersey: 9,700 units · 104 per 100k residents NJ Massachusetts: 8,509 units · 122 per 100k residents MA California: 187,759 units · 482 per 100k residents CA Utah: 4,332 units · 127 per 100k residents UT Colorado: 85,228 units · 1,450 per 100k residents CO Nebraska: 7,603 units · 384 per 100k residents NE Missouri: 17,172 units · 277 per 100k residents MO Kentucky: 16,330 units · 361 per 100k residents KY West Virginia: 23,090 units · 1,305 per 100k residents WV Virginia: 33,425 units · 383 per 100k residents VA Maryland: 32,235 units · 522 per 100k residents MD Connecticut: 7,047 units · 195 per 100k residents CT Rhode Island: no data reported RI Arizona: 87,960 units · 1,184 per 100k residents AZ New Mexico: 23,950 units · 1,133 per 100k residents NM Kansas: 2,152 units · 73.2 per 100k residents KS Arkansas: 8,861 units · 289 per 100k residents AR Tennessee: 30,167 units · 423 per 100k residents TN North Carolina: 58,487 units · 540 per 100k residents NC South Carolina: 33,870 units · 630 per 100k residents SC Delaware: 1,916 units · 186 per 100k residents DE Oklahoma: 4,508 units · 111 per 100k residents OK Louisiana: 24,790 units · 542 per 100k residents LA Mississippi: 3,179 units · 108 per 100k residents MS Alabama: 24,949 units · 488 per 100k residents AL Georgia: 61,318 units · 556 per 100k residents GA D.C.: 2,332 units · 343 per 100k residents DC Hawaii: 7,101 units · 495 per 100k residents HI Texas: 47,749 units · 157 per 100k residents TX Florida: 189,042 units · 836 per 100k residents FL
Units reimbursed · per 100k residents
73.24,930
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Oregon 4,930 /100k
2 Washington 4,262 /100k
3 Montana 3,289 /100k
4 Alaska 2,630 /100k
5 Idaho 2,231 /100k
6 Colorado 1,450 /100k
7 West Virginia 1,305 /100k
8 Arizona 1,184 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
500 tablets69584-0611-50 141,087 Rx · $1,236,271
100 tablets this page69584-0611-10 35,362 Rx · $279,253
90 tablets69584-0611-09 No Medicaid data
1000 tablets69584-0611-90 No Medicaid data
Drug total (last 4 qtrs): 176,449 Rx · 9,666,008 units · $1,515,524 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Methocarbamol — the program that covers self-administered drugs. 17 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Methocarbamol. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$13.41M
Claims incl. refills
1.1M
Beneficiaries
734.7K
Spend / beneficiary
$18.26
Spend / claim
$12.07
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Methocarbamol — the ingredient across all brands.

Top reported reactions

Pain1,731
Nausea1,679
Fatigue1,651
Headache1,300
Diarrhoea1,183
Fall1,096
Dyspnoea1,054

Age at onset

Neonate5
Infant2
Child21
Adolescent18
Adult2,749
Elderly1,386

Reporter sex

22,596 reports
Male · 29%
Female · 70%
Unknown · 0%

Serious outcomes

Hospitalization6,807
Death1,739
Disabling603
Life-threatening535
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 1,772 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
69584-0611-09 90 TABLET in 1 BOTTLE (69584-611-09) — — 2019-08-15 Active
69584-0611-10 You're viewing this 100 TABLET in 1 BOTTLE (69584-611-10) $0.0397 / ea $3.97 2019-08-15 Active
69584-0611-50 500 TABLET in 1 BOTTLE (69584-611-50) $0.0397 / ea $19.85 2019-08-15 Active
69584-0611-90 1000 TABLET in 1 BOTTLE (69584-611-90) $0.0397 / ea $39.70 2019-08-15 Active

You're viewing one of 4 pack sizes for this product.

This pack has the lowest per-ea cost of the 3 priced pack sizes ($0.0397 NADAC).

This pack accounts for about 20% of this product's recent Medicaid fills; most go to the 500 tablets pack. See all packs ↓

Pack size FAQ

What quantity is in NDC 69584-0611-10?
NDC 69584-0611-10 is a 100-count package — 100 tablet in 1 bottle.
What is the difference between NDC 69584-0611-10 and NDC 69584-0611-09?
Both are Methocarbamol 500 mg Tablet — the drug itself is identical. NDC 69584-0611-10 is the 100-count package, while NDC 69584-0611-09 is the 90 tablets package.
What NDC number is used to bill for this package of Methocarbamol 500 mg Tablet?
Bill NDC 69584-0611-10 — the 11-digit billing format is 69584061110. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🔄 Drug Interactions 🔄 Drug / Laboratory Test Interactions 👥 Use in Specific Populations 🤰 Pregnancy 🧒 Pediatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients
🎯 Indications and Usage 56 words ▾

INDICATIONS AND USAGE Methocarbamol is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. Methocarbamol does not directly relax tense skeletal muscles in man.

⏱️ Dosage and Administration 75 words ▾

DOSAGE AND ADMINISTRATION Methocarbamol, 500 mg — Adults: Initial dosage: 3 tablets q.i.d. Maintenance dosage: 2 tablets q.i.d. Methocarbamol, 750 mg — Adults: Initial dosage: 2 tablets q.i.d. Maintenance dosage: 1 tablet q.4h. or 2 tablets t.i.d. Six grams a day are recommended for the first 48 to 72 hours of treatment. (For severe conditions 8 grams a day may be administered). Thereafter, the dosage can usually be reduced to approximately 4 grams a day.

⛔ Contraindications 16 words ▾

CONTRAINDICATIONS Methocarbamol is contraindicated in patients hypersensitive to methocarbamol or to any of the tablet components.

⚠️ Warnings 153 words ▾

WARNINGS Since methocarbamol may possess a general CNS depressant effect, patients receiving methocarbamol tablets should be cautioned about combined effects with alcohol and other CNS depressants. Safe use of methocarbamol has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol.

Therefore, methocarbamol tablets should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see PRECAUTIONS, Pregnancy ) . Use in Activities Requiring Mental Alertness Methocarbamol may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities.

🤒 Adverse Reactions 82 words ▾

ADVERSE REACTIONS Adverse reactions reported coincident with the administration of methocarbamol include: Body as a whole: Anaphylactic reaction, angioneurotic edema, fever, headache Cardiovascular system: Bradycardia, flushing, hypotension, syncope, thrombophlebitis Digestive system: Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting Hemic and lymphatic system: Leukopenia Immune system: Hypersensitivity reactions Nervous system: Amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo Skin and special senses: Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria

🔄 Drug Interactions 36 words ▾

Drug Interactions See WARNINGS and PRECAUTIONS for interaction with CNS drugs and alcohol. Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore, methocarbamol should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents.

🔄 Drug / Laboratory Test Interactions 33 words ▾

Drug/Laboratory Test Interactions Methocarbamol may cause a color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) using nitrosonaphthol reagent and in screening tests for urinary vanillylmandelic acid (VMA) using the Gitlow method.

👥 Use in Specific Populations 195 words ▾

Special populations Elderly The mean (± SD) elimination half-life of methocarbamol in elderly healthy volunteers (mean [± SD] age, 69 [± 4] years) was slightly prolonged compared to a younger (mean [± SD] age, 53.3 [± 8.8] years), healthy population (1.5 [±0.4] hours versus 1.1 [± 0.27] hours, respectively). The fraction of bound methocarbamol was slightly decreased in the elderly versus younger volunteers (41 to 43% versus 46 to 50%, respectively). Renally impaired The clearance of methocarbamol in 8 renally-impaired patients on maintenance hemodialysis was reduced about 40% compared to 17 normal subjects, although the mean (± SD) elimination half-life in these two groups was similar: 1.2 (± 0.6) versus 1.1 (± 0.3) hours, respectively.

Hepatically impaired In 8 patients with cirrhosis secondary to alcohol abuse, the mean total clearance of methocarbamol was reduced approximately 70% compared to that obtained in 8 age- and weight-matched normal subjects. The mean (± SD) elimination half-life in the cirrhotic patients and the normal subjects was 3.38 (±1.62) hours and 1.11 (± 0.27) hours, respectively. The percent of methocarbamol bound to plasma proteins was decreased to approximately 40 to 45% compared to 46 to 50% in the normal subjects.

🤰 Pregnancy 118 words ▾

Pregnancy Teratogenic Effects – Pregnancy Category C Animal reproduction studies have not been conducted with methocarbamol. It is also not known whether methocarbamol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Methocarbamol should be given to a pregnant woman only if clearly needed.

Safe use of methocarbamol has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, methocarbamol should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see WARNINGS ).

🧒 Pediatric Use 19 words ▾

Pediatric Use Safety and effectiveness of methocarbamol in pediatric patients below the age of 16 have not been established.

🆘 Overdosage 101 words ▾

OVERDOSAGE Limited information is available on the acute toxicity of methocarbamol. Overdose of methocarbamol is frequently in conjunction with alcohol or other CNS depressants and includes the following symptoms: nausea, drowsiness, blurred vision, hypotension, seizures, and coma. In post-marketing experience, deaths have been reported with an overdose of methocarbamol alone or in the presence of other CNS depressants, alcohol or psychotropic drugs.

Treatment Management of overdose includes symptomatic and supportive treatment. Supportive measures include maintenance of an adequate airway, monitoring urinary output and vital signs, and administration of intravenous fluids if necessary. The usefulness of hemodialysis in managing overdose is unknown.

🧬 Clinical Pharmacology ~1 min read ▾

CLINICAL PHARMACOLOGY The mechanism of action of methocarbamol in humans has not been established, but may be due to general central nervous system (CNS) depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber. Pharmacokinetics In healthy volunteers, the plasma clearance of methocarbamol ranges between 0.20 and

0.80L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%. Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of methocarbamol also is likely.

Essentially all methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged methocarbamol also are excreted in the urine. Special populations Elderly The mean (± SD) elimination half-life of methocarbamol in elderly healthy volunteers (mean [± SD] age, 69 [± 4] years) was slightly prolonged compared to a younger (mean [± SD] age, 53.3 [± 8.8] years), healthy population (1.5 [±0.4] hours versus 1.1 [± 0.27] hours, respectively).

The fraction of bound methocarbamol was slightly decreased in the elderly versus younger volunteers (41 to 43% versus 46 to 50%, respectively). Renally impaired The clearance of methocarbamol in 8 renally-impaired patients on maintenance hemodialysis was reduced about 40% compared to 17 normal subjects, although the mean (± SD) elimination half-life in these two groups was similar: 1.2 (± 0.6) versus 1.1 (± 0.3) hours, respectively. Hepatically impaired In 8 patients with cirrhosis secondary to alcohol abuse, the mean total clearance of methocarbamol was reduced approximately 70% compared to that obtained in 8 age- and weight-matched normal subjects.

The mean (± SD) elimination half-life in the cirrhotic patients and the normal subjects was 3.38 (±1.62) hours and 1.11 (± 0.27) hours, respectively. The percent of methocarbamol bound to plasma proteins was decreased to approximately 40 to 45% compared to 46 to 50% in the normal subjects.

📦 How Supplied / Storage and Handling 148 words ▾

HOW SUPPLIED Methocarbamol Tablets, USP 500 mg — white, round, convex face, debossed “611” over bisect and “O” below bisect on one side and plain on the reverse side. Available in: Bottles of 90, NDC number 69584-611-09 bottles of 100, NDC number 69584-611-10 bottles of 500, NDC number 69584-611-50 bottles of 1000, NDC number 69584-611-90 Methocarbamol Tablets, USP 750 mg — white, capsule shape, convex face, debossed “612” on one side and debossed “O” on the reverse side. Available in: bottles of 90, NDC number 69584-612-09 bottles of 100, NDC number 69584-612-10 bottles of 500, NDC number 69584-612-50 bottles of 1000, NDC number 69584-612-90 Store at 20°– 25°C (68°– 77°F) [See USP Controlled Room Temperature].

Dispense in tight container. For more information, call Oxford Pharmaceuticals, LLC at 1-844-508‑1455, 8:00 AM to

4.30PM ET, Monday – Friday Manufactured by: OXFORD PHARMACEUTICALS Birmingham, AL 35211 8200004 Rev 12/20 R01

📋 Description 124 words ▾

DESCRIPTION Methocarbamol Tablets, USP, 500 mg and 750 mg, a carbamate derivative of guaifenesin, is a central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties. The chemical name of methocarbamol is 3-(2-methoxyphenoxy)-1, 2-propanediol 1-carbamate and has the empirical formula C 11 H 15 NO 5 . Its molecular weight is 241.24.

The structural formula is shown below. Methocarbamol is a white powder, sparingly soluble in water and chloroform, soluble in alcohol (only with heating) and propylene glycol, and insoluble in benzene and n -hexane. Each tablet, for oral administration, contains either 500 mg or 750 mg of methocarbamol, USP.

The inactive ingredients present are colloidal silicon dioxide, magnesium stearate, povidone, pregelatinized corn starch, purified water, sodium starch glycolate, and stearic acid. str

💬 Information for Patients 46 words ▾

Information for Patients Patients should be cautioned that methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery. Because methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 69584-0427-10 · Oxford 69584-0612-09 · Oxford →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.